Results 21 to 30 of about 2,408 (176)

THE IMPACT OF EVINACUMAB THERAPY ON PEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM PART B OF A PHASE 3 TRIAL

American Journal of Preventive Cardiology, 2023
Therapeutic Area: ASCVD /CVD Risk Reduction Background: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels.
Albert Wiegman, Susanne Greber-Platzer, Shazia Ali, Divya Singh, M. Doortje Reijman, Eliot A Brinton, Min-Ji Charng, Shubha Srinivasan, Carissa Baker-Smith, Seth Baum, Julie Brothers, Jacob Hartz, Patrick M. Moriarty, Poulabi Banerjee, Richard T George, Robert Pordy   +15 more
doaj   +1 more source

Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

Journal of Lipid Research, 2012
In familial hypercholesterolemia (FH), low HDL cholesterol (HDL-C) levels are associated with functional alterations of HDL particles that reduce their capacity to mediate the reverse cholesterol transport (RCT) pathway.
Alexina Orsoni, Elise F. Villard, Eric Bruckert, Paul Robillard, Alain Carrie, Dominique Bonnefont-Rousselot, M. John Chapman, Geesje M. Dallinga-Thie, Wilfried Le Goff, Maryse Guerin   +9 more
doaj   +1 more source

Urinary Neopterin and Microalbuminuria in Patients Treated by Low-density Lipoprotein Apheresis

Pteridines, 2005
Low-density lipoprotein (LDL)-apheresis is a method of extracorporeal elimination of LDL-cholesterol in patients with severe primary lipoprotein disorders.
Cermanová Melanie, Melichar Bohuslav, Solichová Dagmar, Bláha Milan, Bláha Vladimir, Blazek Martin, Mašín Vladimir, Cerman Jaroslav, Zadák Zdenek   +8 more
doaj   +1 more source

Treatment of Homozygous Familial Hypercholesterolemia With EvinacumabNovel Teaching Points

CJC Open, 2022
Patients with homozygous familial hypercholesterolemia (HoFH) have extremely elevated levels of low-density lipoprotein cholesterol (LDL-C), with premature atherosclerosis and aortic valve disease.
Natasha Jeraj, BSc, Shih-Han S. Huang, MD, Brooke A. Kennedy, BSc, Robert A. Hegele, MD   +3 more
doaj   +1 more source

Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India

Asian Journal of Transfusion Science, 2017
Familial hypercholesterolemia (FH) is an autosomal dominant disorder due to mutation of apolipoprotein-B receptor gene causing severe dyslipidemia. Lifestyle modification and medical treatment attenuate the disease progression, but as these fail to ...
Kanchan Dogra, Alpesh Goyal, Rajesh Khadgawat, Yashdeep Gupta, Diptiranjan Rout, Parag Prabhakar Fulzele, Rahul Chaurasia, Poonam Coshic, Kabita Chatterjee   +8 more
doaj   +1 more source

LDL‐aférese no tratamento de hipercolesterolemia familiar: experiência do Hospital Santo António

Revista Portuguesa de Cardiologia, 2015
Resumo: Introdução: A hipercolesterolemia manifestada pelos níveis elevados de colesterol das lipoproteínas de baixa densidade constitui um fator de risco major para o desenvolvimento e progressão da doença aterosclerótica prematura.A adsorção direta de
Isabel Palma, Ana Rita Caldas, Isabel Mangas Palma, José Alexandre Queirós, Anselmo Madureira, José Carlos Oliveira, Paulo Palma, Carlos Correia, Maria Helena Ramos   +8 more
doaj   +1 more source

In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy

Journal of Lipid Research, 2004
LDL can be subfractionated into buoyant (1.020–1.029 g/ml−1), intermediate (1.030–1.040 g/ml−1), and dense (1.041–1.066 g/ml−1) LDLs. We studied the rebound of these LDL-subfractions after LDL apheresis in seven patients with heterozygous familial ...
H.C. Geiss, S. Bremer, P.H.R. Barrett, C. Otto, K.G. Parhofer   +4 more
doaj   +1 more source

Lipoprotein apheresis efficacy and challenges: single center experience

Hematology, Transfusion and Cell Therapy, 2022
Introduction: Lipoprotein apheresis (LA) is an extracorporeal therapy which removes apolipoprotein B-containing particles from the circulation. We evaluated techniques and efficiency of lipoprotein apheresis procedures applied to patients with familial ...
Zehra Narlı Özdemir, Uğur Şahin, Yasin Yıldırım, Cansın Tulunay Kaya, Osman İlhan   +4 more
doaj   +1 more source

Effectiveness of a Novel Low‐Density Lipoprotein Apheresis Device Rheocarna in Patients Undergoing Hemodialysis With Chronic Limb‐Threatening Ischemia: A Single‐Center Retrospective Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Chronic limb‐threatening ischemia (CLTI) is a severe form of lower‐extremity artery disease characterized by distal lesions and microcirculatory impairment, limiting revascularization efficacy. Rheocarna is a direct hemoperfusion low‐density lipoprotein (LDL) adsorption device with potential rheological and anti‐inflammatory ...
Kunihiro Ishioka, Takayasu Ohtake, Kei Ohmori, Chika Shibuya, Tomoki Tsukahara, Mizuki Yamano, Yasuhiro Mochida, Machiko Oka, Kyoko Maesato, Yusuke Tsukamoto, Hidekazu Moriya, Sumi Hidaka, Shuzo Kobayashi   +12 more
wiley   +1 more source

Long‐term prognosis of focal segmental glomerulosclerosis treated with therapeutic low‐density lipoprotein‐apheresis in patients with severe kidney dysfunction and proteinuria

Rheumatology & Autoimmunity, 2023
Background The prognosis of focal segmental glomerulosclerosis patients with nephrotic syndrome is estimated to be 10%–20% in 5 years and 30%–50% in 10 years, leading to end‐stage kidney disease.
Shinji Kitajima, Megumi Osima, Hisayuki Ogura, Shiori Nakagawa, Yuta Yamamura, Taito Miyake, Taro Miyagawa, Tadashi Toyama, Akinori Hara, Norihiko Sakai, Miho Shimizu, Takashi Wada, Yasunori Iwata   +12 more
doaj   +1 more source